Updated on 8 November 2013
In vivo investigation of CD5-2 in a variety of animal models has demonstrated that this drug potently inhibits vascular permeability and promotes angiogenesis, leading to increased blood flow, decreased oedema and faster recovery, for example, in the industry standard hind limb ischemia mouse model.
Dr Thorleif Møller, CEO of Mirrx, commented, "We are very pleased to have entered into this partnership with the Centenary Institute, which to the best of our knowledge has provided the first therapeutic in vivo proof of concept for blocking microRNA binding sites in messenger RNA. Moreover, the partnership has validated our 2nd generation Blockmir design with improved specificity and potency. We look forward to continuing our efforts in developing new therapeutic oligonucleotide drug candidates targeting VE-cadherin together with the world class researchers of the Centenary Institute, and believe that this work will provide a new perspective on the field of microRNA based therapeutics."
Professor Mathew Vadas, Executive Director of the Centenary Institute, said, "Leaky blood vessels, as manifest by tissue swelling that can ultimately obstruct blood supply, is a very important clinical problem from the emergency room all the way to rehabilitation. The potential of a useful drug preventing vascular leak is very exciting and we look forward to its clinical development in collaboration with Mirrx."